期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 110, 期 -, 页码 38-51出版社
ELSEVIER
DOI: 10.1016/j.addr.2016.06.007
关键词
Peptide; Molecular imaging; Chemical modification; Clinical experience
资金
- National Key Basic Research Program of China [2014CB744503]
- National Natural Science Foundation of China [21271030, 51502251, 81471707, 81571743]
Selective receptor-targeting peptide based agents have attracted considerable attention inmolecular imaging of tumor cells that overexpress corresponding peptide receptors due to their unique properties such as rapid clearance from circulation as well as high affinities and specificities for their targets. The rapid growth of chemistry modification techniques has enabled the design and development of various peptide-based imaging agents with enhanced metabolic stability, favorable pharmacokinetics, improved binding affinity and selectivity, better imaging ability as well as biosafety. Among them, many radiolabeled peptides have already been translated into the clinic with impressive diagnostic accuracy and sensitivity. This review summarizes the current status in the development of peptide-based imaging agents with an emphasis on the consideration of probe design including the identification of suitable peptides, the chemical modification of probes and the criteria for clinical translation. Specific examples in clinical trials have been provided as well with respect to their diagnostic capability compared with other FDA approved imaging agents. (C) 2016 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据